Lipofene (Fenofibrate)

Fenofibrate activates the peroxisome proliferator‑activated receptor alpha (PPARα), a nuclear transcription factor that enhances fatty‑acid oxidation, increases lipoprotein lipase activity, and reduces hepatic production of very‑low‑density lipoprotein. These actions collectively lower triglycerides and LDL‑cholesterol while modestly raising HDL‑cholesterol.

The appropriate dose of Lipofene is determined by the prescribing healthcare professional based on the patient’s specific lipid profile, renal and hepatic function, and any concomitant medications. Patients should follow the dosage instructions provided by their prescriber.

Safety of fenofibrate in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Lipofene product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Fenofibrate belongs to the fibrate class, which primarily targets triglyceride reduction and modestly raises HDL‑cholesterol. In contrast, statins mainly lower LDL‑cholesterol. For patients with predominant hypertriglyceridemia or mixed dyslipidemia, fenofibrate may be preferred, whereas statins are first‑line for isolated high LDL‑cholesterol.

Lipofene should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lipofene is taken orally, usually with a meal to improve absorption. The tablet should be swallowed whole with water and not chewed or crushed unless specifically directed by a healthcare professional.

The most serious adverse events include rhabdomyolysis (especially when combined with statins), severe liver injury, acute pancreatitis, gallstone formation, and rare but potentially life‑threatening allergic reactions such as anaphylaxis. Patients should report unexplained muscle pain, dark urine, jaundice, or severe abdominal pain promptly.

Lipofene is contraindicated in patients with known hypersensitivity to fenofibrate or any component of the formulation, active gallbladder disease, severe liver impairment, and those taking gemfibrozil. Caution is also advised for individuals with significant renal dysfunction or those on interacting medications.